FY2025 EPS Estimates for TSE:MDP Raised by Stifel Canada

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Stifel Canada increased their FY2025 earnings per share estimates for shares of Medexus Pharmaceuticals in a report released on Monday, January 13th. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings per share of $0.03 for the year, up from their prior forecast of ($0.03). The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

A number of other equities research analysts also recently issued reports on the company. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research report on Wednesday, January 8th. Stifel Nicolaus increased their price target on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday. Finally, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Stock Performance

Medexus Pharmaceuticals stock opened at C$4.33 on Thursday. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$4.60. The stock has a fifty day moving average of C$2.92 and a 200 day moving average of C$2.60. The stock has a market cap of C$106.21 million, a PE ratio of 86.60 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.